List all articles in the database by published date

GET /articles/?page=2
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 14259,
    "next": "http://api.gregory-ms.com/articles/?page=3",
    "previous": "http://api.gregory-ms.com/articles/",
    "results": [
        {
            "article_id": 946517,
            "title": "Multiple sclerosis in sarcoidosis patients: Two case reports",
            "summary": "Two cases of sarcoidosis referred to our clinic with neurological symptoms. They were diagnosed with multiple sclerosis using non-invasive studies. The first patient refused treatment and died of myocardial infarction 6 months after visiting our clinic. The second received interferon-beta and methotrexate with a favorable outcome after 3 years. Since the possible similar presentation of the two conditions could appear indistinct for certain diagnosis, accurate evaluation of symptoms and...",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36172327/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220929070015&v=2.17.8",
            "published_date": "2022-09-29T10:00:00Z",
            "source": "PubMed",
            "authors": [
                "Masoud Etemadifar",
                "Nahad Sedaghat",
                "Mehri Salari",
                "Armin Mehri",
                "Parsa Tavassoli Naini"
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-29T11:00:17.446310Z",
            "noun_phrases": [
                "sarcoidosis patients",
                "Two case"
            ],
            "doi": "10.1002/ccr3.6332",
            "access": "open"
        },
        {
            "article_id": 946515,
            "title": "Role of RGC-32 in multiple sclerosis and neuroinflammation - few answers and many questions",
            "summary": "Recent advances in understanding the pathogenesis of multiple sclerosis (MS) have brought into the spotlight the major role played by reactive astrocytes in this condition. Response Gene to Complement (RGC)-32 is a gene induced by complement activation, growth factors, and cytokines, notably transforming growth factor β, that is involved in the modulation of processes such as angiogenesis, fibrosis, cell migration, and cell differentiation. Studies have uncovered the crucial role that RGC-32...",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36172382/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220929070015&v=2.17.8",
            "published_date": "2022-09-29T10:00:00Z",
            "source": "PubMed",
            "authors": [
                "Horea Rus",
                "Alexandru Tatomir",
                "Jacob Cuevas",
                "Tudor C. Badea",
                "Dafin F. Muresanu",
                "Violeta Rus"
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-29T11:00:17.442402Z",
            "noun_phrases": [
                "Role",
                "RGC-32",
                "multiple sclerosis",
                "answers",
                "many questions"
            ],
            "doi": "10.3389/fimmu.2022.979414",
            "access": "open"
        },
        {
            "article_id": 947091,
            "title": "Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab",
            "summary": "CONCLUSIONS: Soluble vascular cell adhesion molecule 1 is a suitable pharmacodynamic marker during treatment with NTZ, which is significantly reduced already after the first dose, remains stable in individual patients even on extended interval dosing, and strongly correlates with NTZ SC. Because of the high inter-individual range, absolute levels of sVCAM-1 and NTZ SC are difficult to introduce as treatment monitoring biomarkers in order to predict disease activity in single patients.",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36173556/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220929130511&v=2.17.8",
            "published_date": "2022-09-29T10:00:00Z",
            "source": "PubMed",
            "authors": [],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-29T17:05:12.302317Z",
            "noun_phrases": [
                "Soluble Vascular Cell Adhesion Molecule-1",
                "(sVCAM-1",
                "Natalizumab Serum Concentration",
                "Potential Biomarkers",
                "Pharmacodynamics and Treatment Response",
                "Patients",
                "Multiple Sclerosis Receiving Natalizumab"
            ],
            "doi": "10.1007/s40263-022-00953-x",
            "access": "restricted"
        },
        {
            "article_id": 947090,
            "title": "Aging microglia: old friends greet new enemies",
            "summary": "No abstract",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36173626/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220929130511&v=2.17.8",
            "published_date": "2022-09-29T10:00:00Z",
            "source": "PubMed",
            "authors": [
                "V. Wee Yong",
                "Yifei Dong"
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-29T17:05:12.298351Z",
            "noun_phrases": [
                "old friends",
                "new enemies"
            ],
            "doi": "10.18632/aging.204317",
            "access": "open"
        },
        {
            "article_id": 947092,
            "title": "Effects of anti-Inflammatory-antioxidant-rich diet and co-supplemented synbiotics intervention in patients with progressive forms of multiple sclerosis: a single-center, single-blind randomized clinical trial",
            "summary": "CONCLUSION: Synbiotics supplementation and adherence to an anti-inflammatory-antioxidant-rich diet reduced intestinal inflammation and improved clinical manifestations in progressive forms of MS.Trial registration: Iranian Registry of Clinical Trials identifier: IRCT20141108019853N7..",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36173031/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220929130511&v=2.17.8",
            "published_date": "2022-09-29T10:00:00Z",
            "source": "PubMed",
            "authors": [],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-29T17:05:12.304662Z",
            "noun_phrases": [
                "Effects",
                "anti-Inflammatory-antioxidant-rich diet",
                "-supplemented synbiotics intervention",
                "patients",
                "progressive forms",
                "multiple sclerosis",
                "a single-center, single-blind randomized clinical trial"
            ],
            "doi": "10.1080/1028415X.2022.2128010",
            "access": "restricted"
        },
        {
            "article_id": 946514,
            "title": "Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data",
            "summary": "CONCLUSION: This study suggests that AMs are effective in MS patients, but their use should be tailored on every patient as even low dosages can be poorly tolerated. AEs, including neurological ones, are common.",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36172491/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220929070015&v=2.17.8",
            "published_date": "2022-09-29T10:00:00Z",
            "source": "PubMed",
            "authors": [
                "Massimiliano Calabrese",
                "Enrico Finazzi Agrò",
                "Elena Andretta",
                "Luca Orecchia",
                "Antonietta Furlan",
                "Cristina Zuliani"
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-29T11:00:17.437651Z",
            "noun_phrases": [
                "neurogenic overactive bladder",
                "multiple sclerosis"
            ],
            "doi": "10.1177/17562872221122484",
            "access": "open"
        },
        {
            "article_id": 944604,
            "title": "Cladribine-induced liver injury: Implications for practice",
            "summary": "No abstract",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36169282/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220928133016&v=2.17.8",
            "published_date": "2022-09-28T10:00:00Z",
            "source": "PubMed",
            "authors": [
                "Wallace J Brownlee"
            ],
            "relevant": null,
            "ml_prediction_gnb": true,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-28T17:30:17.201127Z",
            "noun_phrases": [
                "Cladribine-induced liver injury",
                "Implications",
                "practice"
            ],
            "doi": "10.1177/13524585221125370",
            "access": "restricted"
        },
        {
            "article_id": 945830,
            "title": "Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network",
            "summary": "CONCLUSIONS: Contrary to previous interpretations, patients with SPMS progress at greatly different rates. Our identification of distinct trajectories can guide better patient selection in future phase 3 SPMS clinical trials. Additionally, distinct trajectories could reflect heterogeneous pathological mechanisms of progression.",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36171104/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220929010011&v=2.17.8",
            "published_date": "2022-09-28T10:00:00Z",
            "source": "PubMed",
            "authors": [
                "Murat Terzi",
                "Melinda Magyari",
                "Maria Trojano",
                "Tim Spelman",
                "Jan Hillert",
                "Sandra Vukusic",
                "Maria Pia Sormani",
                "Tomas Kalincik",
                "Helmut Butzkueven",
                "Pietro Iaffaldano",
                "Alessio Signori",
                "Dana Horakova",
                "Fabio Pellegrini",
                "Robert Hyde",
                "Pamela A McCombe",
                "Olga Skibina",
                "Raed Alroughani",
                "Sara Eichau",
                "Per Soelberg Sørensen",
                "Bassem Yamout",
                "Marc Girard",
                "Serkan Ozakbas",
                "Chao Zhu",
                "Anneke van der Walt",
                "Johannes Lorscheider",
                "Eva Havrdova",
                "Vincent Van Pesch",
                "Oliver Gerlach",
                "Julie Prevost",
                "Nils Koch-Henriksen",
                "Francois Grand'Maison",
                "Riadh Gouider",
                "Tamara Castillo-Trivino",
                "Maria Jose Sa",
                "Koen de Gans",
                "Samia Khoury",
                "José Luis Sánchez-Menoyo",
                "Saloua Mrabet"
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-29T05:00:12.399698Z",
            "noun_phrases": [
                "Heterogeneity",
                "long-term disability trajectories",
                "patients",
                "secondary progressive MS",
                "a latent class analysis",
                "Big MS Data network"
            ],
            "doi": "10.1136/jnnp-2022-329987",
            "access": "restricted"
        },
        {
            "article_id": 944603,
            "title": "Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders",
            "summary": "In recent years, several disease-modifying therapies have been developed for the treatment of multiple sclerosis (MS). Cladribine transiently depletes B and T lymphocytes, with subsequent gradual cell recovery. No cases are reported in literature describing Cladribine drug-induced liver injury (DILI). We describe the case of a 19-year-old woman who developed acute idiosyncratic liver injury 12 days after treatment with Cladribine. Post-marketing adverse event reporting is of paramount importance...",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36169305/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220928133016&v=2.17.8",
            "published_date": "2022-09-28T10:00:00Z",
            "source": "PubMed",
            "authors": [
                "Alessandra Protti",
                "Lorenzo Saraceno",
                "Elio Clemente Agostoni",
                "Fiammetta Pirro",
                "Rosa Stigliano"
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-28T17:30:17.198886Z",
            "noun_phrases": [
                "Cladribine treatment",
                "multiple sclerosis",
                "first case",
                "associated hepatic disorders"
            ],
            "doi": "10.1177/13524585221125360",
            "access": "restricted"
        },
        {
            "article_id": 944599,
            "title": "Considering the Future of Pediatric Multiple Sclerosis Trials After the CONNECT Open-Label Randomized Trial",
            "summary": "No abstract",
            "link": "https://pubmed.ncbi.nlm.nih.gov/36169961/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220928133016&v=2.17.8",
            "published_date": "2022-09-28T10:00:00Z",
            "source": "PubMed",
            "authors": [
                "Omar Abdel-Mannan",
                "Yael Hacohen",
                "Olga Ciccarelli"
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2022-09-28T17:30:17.183897Z",
            "noun_phrases": [
                "the Future",
                "Pediatric Multiple Sclerosis Trials",
                "the CONNECT Open-Label Randomized Trial"
            ],
            "doi": "10.1001/jamanetworkopen.2022.30451",
            "access": "restricted"
        }
    ]
}